ABT-122(靶向肿瘤坏死因子和白介素-17A的双可变域免疫球蛋白)治疗甲氨蝶呤应答不佳的银屑病关节炎患者的II期研究
这项12周双盲平行分组II期研究纳入240例甲氨蝶呤应答不佳的活动性银屑病关节炎患者,随机接受ABT-122(每周120或240 mg)、阿达木单抗(每两周40 mg)或安慰剂。ABT-122两个剂量组第12周ACR20应答率(64.8-75.3%)优于安慰剂(25.0%)(P < 0.001),与阿达木单抗(68.1%)相似;安全性与阿达木单抗相似,未报告严重感染或全身超敏反应。
要点
- ABT-122两个剂量组ACR20应答率64.8-75.3%,优于安慰剂25.0%(P < 0.001),与阿达木单抗68.1%相似。
- ABT-122两个剂量组ACR50(36.6-53.4%)和ACR70(22.5-31.5%)均优于安慰剂(12.5%和4.2%)(P < 0.05)。
- ABT-122 120 mg组PASI75为74.4%、PASI90为48.8%;240 mg组分别为77.6%和46.9%;阿达木单抗组分别为57.6%和45.5%。
核心结论
- 在12周治疗过程中,ABT-122对TNF和IL-17A的双重中和在银屑病关节炎患者中的疗效和安全性与他克莫司(阿达木单抗)相似,且未显示出广泛差异。
研究设计与样本
- 12周双盲、平行分组II期研究,纳入240例对甲氨蝶呤应答不佳的活动性银屑病关节炎患者。
- 患者随机接受ABT-122(每周120或240 mg)、阿达木单抗(每两周40 mg)或安慰剂。
主要发现
- ABT-122两个剂量组第12周ACR20应答率为64.8-75.3%,优于安慰剂组的25.0%(P < 0.001),与阿达木单抗组的68.1%相似。
- ABT-122两个剂量组ACR50应答率为36.6-53.4%,ACR70应答率为22.5-31.5%,均优于安慰剂组(分别为12.5%和4.2%)(P < 0.05)。
- 在符合条件的患者中,安慰剂组、阿达木单抗组、ABT-122 120 mg每周组和ABT-122 240 mg每周组的PASI75应答率分别为27.3%、57.6%、74.4%和77.6%,PASI90应答率分别为18.2%、45.5%、48.8%和46.9%。
- 治疗中出现的不良事件(包括感染)频率在所有治疗组间相似,未导致停药;ABT-122未报告严重感染或全身超敏反应。
关键数值与推荐
- 主要疗效终点为第12周达到美国风湿病学会ACR20应答标准的患者比例。
- 次要和探索性12周终点包括ACR50和ACR70应答率,以及在体表面积受累≥3%的银屑病患者中达到PASI75和PASI90应答标准的患者比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate. METHODS: Patients (n = 240) were randomized to receive ABT-122 (120 or 240 mg every week), adalimumab (40 mg every other week), or placebo in a 12-week double-blind, parallel-group study. The primary efficacy end point was the proportion of patients achieving ≥20% improvement in disease activity according to the American College of Rheumatology response criteria (ACR20) at week 12. Secondary and exploratory 12-week end points included 50% improvement (ACR50) and 70% improvement (ACR70) response rates, and proportion of patients meeting the Psoriasis Area and Severity Index (PASI) response criteria for ≥75% (PASI75) and ≥90% (PASI90) improvement in skin scores among those with ≥3% of their body surface area affected by psoriasis. RESULTS: In both ABT-122 dose groups, ACR20 response rates at week 12 (64.8-75.3%) were superior to that in patients receiving placebo (25.0%) (P < 0.001) but similar to that in patients receiving adalimumab (68.1%). ACR50 and ACR70 response rates were also superior in both ABT-122 dose groups (36.6-53.4% and 22.5-31.5%, respectively) compared to the placebo group (12.5% and 4.2%, respectively) (P < 0.05). Among eligible patients in the placebo, adalimumab, ABT-122 120 mg every week, and ABT-122 240 mg every week treatment groups, PASI75 responses were achieved in 27.3%, 57.6%, 74.4%, and 77.6% of patients, respectively, whereas PASI90 responses were achieved in 18.2%, 45.5%, 48.8%, and 46.9% of patients, respectively. Frequencies of treatment-emergent adverse events, including infections, were similar across all treatment groups, causing no discontinuations. No serious infections or systemic hypersensitivity reactions were reported with ABT-122. CONCLUSION: Dual neutralization of TNF and IL-17A with ABT-122 had efficacy and safety that was similar to, and not broadly differentiated from, that of adalimumab over a 12-week treatment course in patients with PsA.
引用
- Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2018. PMID: 29855175. doi:10.1002/art.40579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。